https://orcid.org/0000-0002-7265-1764
Abstract
Graft-versus-host disease (GVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation, a widely used therapy for hematologic malignancies and blood disorders. Here, we report an unexpected role of cytokine leukemia inhibitory factor (LIF) in protecting against GVHD development. Administrating recombinant LIF protein (rLIF) protects mice from GVHD-induced tissue damage and lethality without compromising the graft-versus-leukemia activity, which is crucial to prevent tumor relapse. We found that rLIF decreases the infiltration and activation of donor immune cells and protects intestinal stem cells to ameliorate GVHD. Mechanistically, rLIF downregulates IL-12–p40 expression in recipient dendritic cells after irradiation through activating STAT1 signaling, which results in decreased major histocompatibility complex II levels on intestinal epithelial cells and decreased donor T-cell activation and infiltration. This study reveals a previously unidentified protective role of LIF for GVHD-induced tissue pathology and provides a potential effective therapeutic strategy to limit tissue pathology without compromising antileukemic efficacy.
Key Points
LIF protects mice against GVHD by reducing the infiltration and activation of donor immune cells and protecting intestinal stem cells.
LIF decreases IL-12 levels in recipient dendritic cells and MHC-II levels on intestinal epithelia to reduce T-cell activation and GVHD-induced damage.
References
1.
Zeiser
R
, Blazar
BR
. Acute graft-versus-host disease - biologic process, prevention, and therapy
. N Engl J Med
. 2017
;377
(22
):2167
-2179
.2.
Gyurkocza
B
, Sandmaier
BM
. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
. Blood
. 2014
;124
(3
):344
-353
.3.
Koyama
M
, Hill
GR
. The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease
. Blood
. 2019
;134
(24
):2139
-2148
.4.
Paczesny
S
. Biomarkers for posttransplantation outcomes
. Blood
. 2018
;131
(20
):2193
-2204
.5.
Koyama
M
, Mukhopadhyay
P
, Schuster
IS
, et al. MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota
. Immunity
. 2019
;51
(5
):885
-898.e887
.6.
Fu
YY
, Egorova
A
, Sobieski
C
, et al. T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation
. Immunity
. 2019
;51
(1
):90
-103.e103
.7.
Zhang
C
, Liu
J
, Wang
J
, Hu
W
, Feng
Z
. The emerging role of leukemia inhibitory factor in cancer and therapy
. Pharmacol Ther
. 2021
;221
:107754
.8.
Wang
H
, Wang
J
, Zhao
Y
, et al. LIF is essential for ISC function and protects against radiation-induced gastrointestinal syndrome
. Cell Death Dis
. 2020
;11
(7
):588
.9.
Yaftiyan
A
, Eskandarian
M
, Jahangiri
AH
, Kazemi Sefat
NA
, Moazzeni
SM
. Leukemia inhibitory factor (LIF) modulates the development of dendritic cells in a dual manner
. Immunopharmacol Immunotoxicol
. 2019
;41
(3
):455
-462
.10.
Jeannin
P
, Duluc
D
, Delneste
Y
. IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-gamma
. Immunotherapy
. 2011
;3
(suppl 4
):23
-26
.11.
Janssens
K
, Van den Haute
C
, Baekelandt
V
, et al. Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis
. Brain Behav Immun
. 2015
;45
:180
-188
.12.
Reinhardt
RL
, Hong
S
, Kang
SJ
, Wang
ZE
, Locksley
RM
. Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation
. J Immunol
. 2006
;177
(3
):1618
-1627
.13.
Nabekura
T
, Shibuya
K
, Takenaka
E
, et al. Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice
. Proc Natl Acad Sci U S A
. 2010
;107
(43
):18593
-18598
.14.
Inoue
T
, Ikegame
K
, Kaida
K
, et al. Host Foxp3+CD4+ regulatory T cells act as a negative regulator of dendritic cells in the peritransplantation period
. J Immunol
. 2016
;196
(1
):469
-483
.15.
Lee
SM
, Park
HY
, Suh
YS
, et al. Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway
. Proc Natl Acad Sci U S A
. 2017
;114
(29
):E5881
-E5890
.16.
Lamarthee
B
, Marchal
A
, Charbonnier
S
, et al. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction
. Nat Commun
. 2021
;12
(1
):6446
.17.
Zhao
K
, Zhao
D
, Huang
D
, et al. Interleukin-22 aggravates murine acute graft-versus-host disease by expanding effector T cell and reducing regulatory T cell
. J Interferon Cytokine Res
. 2014
;34
(9
):707
-715
.18.
Lamarthee
B
, Malard
F
, Gamonet
C
, et al. Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10
. Mucosal Immunol
. 2016
;9
(2
):309
-321
.19.
Lindemans
CA
, Calafiore
M
, Mertelsmann
AM
, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration
. Nature
. 2015
;528
(7583
):560
-564
.20.
Hanash
AM
, Dudakov
JA
, Hua
G
, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease
. Immunity
. 2012
;37
(2
):339
-350
.21.
Cheroutre
H
, Lambolez
F
, Mucida
D
. The light and dark sides of intestinal intraepithelial lymphocytes
. Nat Rev Immunol
. 2011
;11
(7
):445
-456
.22.
Cao
W
, Yang
Y
, Wang
Z
, et al. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease
. Immunity
. 2011
;35
(2
):273
-284
.23.
Takashima
S
, Martin
ML
, Jansen
SA
, et al. T cell-derived interferon-gamma programs stem cell death in immune-mediated intestinal damage
. Sci Immunol
. 2019
;4
(42
):eaay8556
.24.
Yang
W
, Deng
H
, Zhu
S
, et al. Size-transformable antigen-presenting cell-mimicking nanovesicles potentiate effective cancer immunotherapy
. Sci Adv
. 2020
;6
(50
):eabd1631
.25.
Wosen
JE
, Ilstad-Minnihan
A
, Co
JY
, et al. Human intestinal enteroids model MHC-II in the gut epithelium
. Front Immunol
. 2019
;10
:1970
.26.
Van Der Kraak
LA
, Schneider
C
, Dang
V
, et al. Genetic and commensal induction of IL-18 drive intestinal epithelial MHCII via IFNgamma
. Mucosal Immunol
. 2021
;14
(5
):1100
-1112
.27.
Herndler-Brandstetter
D
, Ishigame
H
, Shinnakasu
R
, et al. KLRG1(+) effector CD8(+) T cells lose KLRG1, differentiate into all memory T cell lineages, and convey enhanced protective immunity
. Immunity
. 2018
;48
(4
):716
-729.e718
.28.
Edwards
J
, Wilmott
JS
, Madore
J
, et al. CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment
. Clin Cancer Res
. 2018
;24
(13
):3036
-3045
.29.
Garris
CS
, Arlauckas
SP
, Kohler
RH
, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12
. Immunity
. 2018
;49
(6
):1148
-1161.e1147
.30.
Tait Wojno
ED
, Hunter
CA
, Stumhofer
JS
. The immunobiology of the interleukin-12 family: room for discovery
. Immunity
. 2019
;50
(4
):851
-870
.31.
Das
R
, Chen
X
, Komorowski
R
, Hessner
MJ
, Drobyski
WR
. Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease
. Blood
. 2009
;113
(10
):2352
-2362
.32.
Cope
A
, Le Friec
G
, Cardone
J
, Kemper
C
. The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching
. Trends Immunol
. 2011
;32
(6
):278
-286
.33.
Roney
K
. Bone marrow-derived dendritic cells
. Methods Mol Biol
. 2019
;1960
:57
-62
.34.
Mizoguchi
Y
, Okada
S
. Inborn errors of STAT1 immunity
. Curr Opin Immunol
. 2021
;72
:59
-64
.35.
Totten
SP
, Im
YK
, Cepeda Canedo
E
, et al. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer
. Nat Commun
. 2021
;12
(1
):3299
.36.
Longman
RS
, Braun
D
, Pellegrini
S
, Rice
CM
, Darnell
RB
, Albert
ML
. Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-alpha/beta on antigen cross-presentation
. Blood
. 2007
;109
(3
):1113
-1122
.37.
Pramanik
R
, Jorgensen
TN
, Xin
H
, Kotzin
BL
, Choubey
D
. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility
. J Biol Chem
. 2004
;279
(16
):16121
-16127
.38.
He
F
, Ge
W
, Martinowich
K
, et al. A positive autoregulatory loop of Jak-STAT signaling controls the onset of astrogliogenesis
. Nat Neurosci
. 2005
;8
(5
):616
-625
.39.
Liu
W
, Miao
C
, Zhang
S
, et al. VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance
. Signal Transduct Target Ther
. 2021
;6
(1
):322
.40.
Miklossy
G
, Hilliard
TS
, Turkson
J
. Therapeutic modulators of STAT signalling for human diseases
. Nat Rev Drug Discov
. 2013
;12
(8
):611
-629
.41.
Fu
J
, Wu
Y
, Nguyen
H
, et al. T-bet promotes acute graft-versus-host disease by regulating recipient hematopoietic cells in mice
. J Immunol
. 2016
;196
(7
):3168
-3179
.42.
Yue
X
, Wu
L
, Hu
W
. The regulation of leukemia inhibitory factor
. Cancer Cell Microenviron
. 2015
;2
(3
):e877
.43.
Holtan
SG
, Shabaneh
A
, Betts
BC
, et al. Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease
. JCI Insight
. 2019
;5
(17
):e129762
.44.
Bastian
D
, Wu
Y
, Betts
BC
, Yu
XZ
. The IL-12 cytokine and receptor family in graft-vs.-host disease
. Front Immunol
. 2019
;10
:988
.45.
Villarino
AV
, Kanno
Y
, O'Shea
JJ
. Mechanisms and consequences of Jak-STAT signaling in the immune system
. Nat Immunol
. 2017
;18
(4
):374
-384
.46.
Niwa
H
, Ogawa
K
, Shimosato
D
, Adachi
K
. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells
. Nature
. 2009
;460
(7251
):118
-122
.47.
Liang
XH
, Deng
WB
, Li
M
, et al. Egr1 protein acts downstream of estrogen-leukemia inhibitory factor (LIF)-STAT3 pathway and plays a role during implantation through targeting Wnt4
. J Biol Chem
. 2014
;289
(34
):23534
-23545
.48.
Yue
X
, Zhao
Y
, Zhang
C
, et al. Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction
. Oncotarget
. 2016
;7
(4
):3777
-3790
.49.
Yu
H
, Yue
X
, Zhao
Y
, et al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers
. Nat Commun
. 2014
;5
:5218
.50.
Zhang
YS
, Xin
DE
, Wang
Z
, et al. STAT4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation
. EMBO J
. 2019
;38
(6
):e99595
.51.
Yu
Y
, Wang
D
, Liu
C
, et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORgammat in mice
. Blood
. 2011
;118
(18
):5011
-5020
.© 2022 by The American Society of Hematology
2022
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal